ECBS 2017 - BS DOCUMENTS

25 October 2017

WHO/BS/2017.2306 Collaborative study for Proposed 1 st WHO International Standard for Lupus (anti-dsDNA) antibodies (15/174) WHO/BS/2017.2306 Collaborative study for Proposed 1 st WHO International Standard for Lupus (anti-dsDNA) antibodies (15/174)

25 October 2017

WHO/BS/2017.2307 A WHO collaborative study to evaluate a candidate IS for anti-Typhoid capsular Vi polysaccharide IgG (Human) WHO/BS/2017.2307 A WHO collaborative study to evaluate a candidate IS for anti-Typhoid capsular Vi polysaccharide IgG (Human)

25 October 2017

WHO/BS/2017.2308 Collaborative Study to Evaluate the Proposed 3rd WHO IS for Hepatitis A Virus (HAV) for Nucleic Acid Amplification Technology (NAT)-Based Assays WHO/BS/2017.2308 Collaborative Study to Evaluate the Proposed 3rd WHO IS for Hepatitis A Virus (HAV) for Nucleic Acid Amplification Technology (NAT)-Based Assays

25 October 2017

WHO/BS/2017.2309 Report on a Collaborative Study for Proposed Candidate 1st IS for the biological activities of Rituximab WHO/BS/2017.2309 Report on a Collaborative Study for Proposed Candidate 1st IS for the biological activities of Rituximab

25 October 2017

WHO/BS/2017.2312 WHO International Collaborative Study of the Proposed 2nd IS for Parathyroid Hormone 1-34, Recombinant, Human WHO/BS/2017.2312 WHO International Collaborative Study of the Proposed 2nd IS for Parathyroid Hormone 1-34, Recombinant, Human

25 October 2017

WHO/BS/2017.2313 Report on the WHO Collaborative study to establish IS for potency assays of Oral Polio Vaccine WHO/BS/2017.2313 Report on the WHO Collaborative study to establish IS for potency assays of Oral Polio Vaccine

25 October 2017

WHO/BS/2017.2314 International Collaborative Study to Establish the 4th WHO IS for HIV-1 NAT Assays WHO/BS/2017.2314 International Collaborative Study to Establish the 4th WHO IS for HIV-1 NAT Assays

25 October 2017

WHO/BS/2017.2315 Collaborative Study for Evaluation of Proposed 2nd IS for Pertussis Toxin Code: 15/126 WHO/BS/2017.2315 Collaborative Study for Evaluation of Proposed 2nd IS for Pertussis Toxin Code: 15/126

25 October 2017

WHO/BS/2017.2316 WHO collaborative study to assess the suitability of the 1st IS and the 1st International Reference Panel for antibodies to Ebola virus WHO/BS/2017.2316 WHO collaborative study to assess the suitability of the 1st IS and the 1st International Reference Panel for antibodies to Ebola virus

25 October 2017

WHO/BS/2017.2317 Collaborative study to evaluate the proposed WHO 1st International Reference Panel for genomic KRAS codons 12 and 13 mutations WHO/BS/2017.2317 Collaborative study to evaluate the proposed WHO 1st International Reference Panel for genomic KRAS codons 12 and 13 mutations

25 October 2017

WHO/BS/2017.2318 Report on the WHO collaborative study to establish the 1st IS for antiserum to Respiratory Syncytial Virus WHO/BS/2017.2318 Report on the WHO collaborative study to establish the 1st IS for antiserum to Respiratory Syncytial Virus

25 October 2017

WHO/BS/2017.2319 Requests to initiate new WHO reference material projects for vaccines andrelated substances WHO/BS/2017.2319 Requests to initiate new WHO reference material projects for vaccines andrelated substances

25 October 2017

WHO/BS/2017.2320 Requests to initiate new WHO reference material projects for blood productsand IVDs WHO/BS/2017.2320 Requests to initiate new WHO reference material projects for blood productsand IVDs

25 October 2017

WHO/BS/2017.2321 Collaborative Study to establish the 1st WHO IS for Human Herpes Virus 6B (HHV-6B) DNA for nucleic acid amplification technique (NAT)-based assays WHO/BS/2017.2321 Collaborative Study to establish the 1st WHO IS for Human Herpes Virus 6B (HHV-6B) DNA for nucleic acid amplification technique (NAT)-based assays

25 October 2017

WHO/BS/2017.2322 Report of the WHO Collaborative Study to establish the First IS for Detection of IgG antibodies to Cytomegalovirus (anti-CMV IgG) WHO/BS/2017.2322 Report of the WHO Collaborative Study to establish the First IS for Detection of IgG antibodies to Cytomegalovirus (anti-CMV IgG)

25 October 2017

WHO/BS/2017.2323 Report on a Collaborative Study for Proposed 1st IS for Infliximab WHO/BS/2017.2323 Report on a Collaborative Study for Proposed 1st IS for Infliximab

25 October 2017

WHO/BS/2017.2324 Proposed WHO Reference Reagent for Activated Blood Coagulation Factor X(FXa), Human WHO/BS/2017.2324 Proposed WHO Reference Reagent for Activated Blood Coagulation Factor X(FXa), Human

25 October 2017

WHO/BS/2017.2325 An International Collaborative Study to Establish the 2nd IS for Activated Factor IX (FIXa) WHO/BS/2017.2325 An International Collaborative Study to Establish the 2nd IS for Activated Factor IX (FIXa)

25 October 2017

WHO/BS/2017.2326 Collaborative Study on the 1st IS for Blood Coagulation Factor XII, Plasma:  Assignment of Functional (FXII:C) and Antigen values (FXII:AG) WHO/BS/2017.2326 Collaborative Study on the 1st IS for Blood Coagulation Factor XII, Plasma:  Assignment of Functional (FXII:C) and Antigen values (FXII:AG)

25 October 2017

WHO/BS/2017.2328 Proposal for a New/ Replacement International Reference Material WHO/BS/2017.2328 Proposal for a New/ Replacement International Reference Material

25 October 2017

WHO/BS/2017.2329 Collaborative study to evaluate the proposed 1st WHO IS for Plasmodium falciparum antigens WHO/BS/2017.2329 Collaborative study to evaluate the proposed 1st WHO IS for Plasmodium falciparum antigens

25 October 2017

WHO/BS/2017.2330 Collaborative Study to Evaluate a Candidate WHO IS for Chikungunya Virus for Nucleic Acid Amplification Technique (NAT)-Based Assays WHO/BS/2017.2330 Collaborative Study to Evaluate a Candidate WHO IS for Chikungunya Virus for Nucleic Acid Amplification Technique (NAT)-Based Assays